The ICM addresses brain and spinal cord disorders by accelerating 

the development of new health solutions

Target markets

• 

Biotechnology

• 

Medical technology

• 

Digital health

Medtech approaches

Identified biomarkers can be circulating 

molecules, neuroimaging signals, 

electroencephalographic traces, 

responses to cognitive tests or other 

«markers». Those new markers and their 

combination are identified at ICM by 

capitalizing on extensive patients cohorts 

and through the development of new 

technologies, used as measurement tools 

as well as a means to modulate brain 

activity: deep brain stimulation, 

therapeutic ultrasounds, transcranial 

magnetic stimulation, etc. are being 

developed at the ICM Carnot Institute 

thanks to 7,000 sqm of technological  

core facilities.

Personalised Medicine

The ICM has structured its research 

strategy into key thematic and transversal 

axis according to the unmet needs of 

«translational» research in the field of 

Neuroscience. 
Patient cohorts, biomarkers identification 

and the validation of new therapeutic 

targets allow for patients affected by 

Parkinson’s disease, Alzheimer’s disease, 

multiple sclerosis or neuro-oncological 

tumors to benefit from personalized 

diagnosis and foresight into how they will 

respond to treatments.

http://research.icm-institute.org

The ICM Carnot Institute is comprised of a research center, a 

center for clinical investigation and an incubator for start-ups 

dedicated to finding solutions for diseases and disorders of 

the central nervous system.

Headquartered in a 22,000 sqm building equipped with the 

latest technological core facilities, our goal is to promote 

strong partnerships as a means to accelerate translational 

research and respond to industry actors unmet needs.

© JP Parienté

 
EEG

 
CENIR Human MRI cor facility